Catalina Capital Group LLC Has $219,000 Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Catalina Capital Group LLC trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 307 shares of the biopharmaceutical company’s stock after selling 36 shares during the quarter. Catalina Capital Group LLC’s holdings in Regeneron Pharmaceuticals were worth $219,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Rakuten Securities Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares during the last quarter. FSA Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at $26,000. Fairfield Financial Advisors LTD purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $37,000. Truvestments Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $39,000. Finally, Valley Wealth Managers Inc. bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at about $49,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $666.85 on Tuesday. The firm has a 50-day moving average of $720.81 and a two-hundred day moving average of $921.72. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 1 year low of $663.43 and a 1 year high of $1,211.20. The stock has a market cap of $73.28 billion, a price-to-earnings ratio of 16.50, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on REGN. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Finally, UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,004.57.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.